| Project/Area Number |
17591720
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
YASUGI Toshiharu The University of Tokyo, Faculty of Medicine, Lecturer, 医学部附属病院, 講師 (20251267)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ODA Katsutoshi The University of Tokyo, Faculty of Medicine, Assistant, 医学部附属病院, 助手 (30359608)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2006: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 2005: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Keywords | endometrial carcinomas / p53 / tumor suppressor protein / prognosis / PI3K pathway |
|---|
| Research Abstract |
Two types of endometrial cancer have been described In previous studies. Type 1 endometrial cancer is characterized as estrogen dependent with excellent prognosis, and type 2 as estrogen independent with poor prognosis. PTEN mutations occur at high frequency in endometrial carcinomas. Although It had been controversial whether PTEN mutation is associated with prognosis, we previously reported that PTEN mutation only outside exons 5-7 is a favorable prognostic factor in endometrial carcinomas. Over expression of p53 is also frequent and contributes to the poor survival in endometrial carcinomas. Mutations or amplifications of PIK3CA. which encodes the catalytic subunit of PI3K, have been reported in many human cancers.
To elucidate the relationship between PTEN mutation and p53 overexpression, we analyzed PTEN, p53 status and estrogen receptor and progesterone receptor. We also assessed PIK3CA status in endometrial carcinomas.
In the series of study, we show the absence of P53 overexpression, PTEN mutations and clinical stage are favorable and independent prognostic factors in endometrial carcinomas. We also reported frequent coexistence of PIK3CA and PTEN mutations in endometrial carcinomas. Moreover we show that PIK3CA copy number may change in endometrial carcinomas.
|
